Bank ABC Islamic named ‘Best Sukuk House in Bahrain'
Bank ABC Islamic has been recognised as the 'Best Sukuk House in Bahrain' at the Euromoney Islamic Awards 2025.
This award highlights the bank's excellence in Islamic finance and its commitment to offering Sharia-compliant banking solutions across the MENA region and globally. The prestigious award was presented on May 20 in Dubai, at a ceremony attended by industry experts and peers.
By offering superior Sharia-compliant financial products and services, Bank ABC Islamic has significantly expanded its market share across the MENA region and served clients across its network markets. The bank has provided inclusive Islamic financial solutions tailored to regional needs, further strengthening its foothold in the MENA region. The Islamic Bank's alignment with sustainability principles further underscores its commitment to generating positive social and environmental outcomes alongside financial returns.
Commenting on this achievement, Hammad Hassan, Managing Director, Bank ABC Islamic & Group Head of Islamic Banking at Bank ABC, said: 'It is a great honour to be named 'Best Sukuk House in Bahrain' at the Euromoney Islamic Finance Awards 2025. This award reflects our commitment to advancing Islamic finance in the region and globally, and our efforts dedicated towards delivering genuine Sharia-compliant financial solutions aligned with Bank ABC's overarching sustainability goals. I thank Euromoney for recognising our growth and innovation in our Islamic Banking offering, as well as the team behind Bank ABC Islamic and our product partners across Bank ABC Group for their focused efforts and perseverance."
Bank ABC Islamic has been instrumental in facilitating high-profile Sukuk transactions, including multi-million-dollar issuances that underscore its expertise and thorough understanding of client needs. The bank recently played a key role as joint lead manager in a landmark sustainable Sukuk issuance and served as co-lead manager in a major green Sukuk offering by a prominent Gulf conglomerate.
Over the last few years, the bank has played a pivotal role in enabling large corporate Issuers from the US and Europe tap Islamic liquidity from the region for the first time, and these mandates have received largescale industry recognition. This was achieved through the close collaboration of Bank ABC Islamic's structuring team and Bank ABC Group's Debt Capital Markets platform, with its strong product and distribution capabilities, which come together very successfully.
alburaq, Bank ABC Islamic's fully digital Islamic banking window, has also seen great success. Designed to deliver seamless Sharia-compliant digital banking services, alburaq has reinforced Bank ABC Islamic's position as a frontrunner in state-of-the-art Islamic finance.
Ben Naylor, Global Head of Research, Euromoney, commented: ''Bank ABC Islamic led Bahrain's Sukuk market, closing 16 mandates worth $12 billion. Highlights include landmark deals for AerCap, Turkey, and Dubai Islamic Bank. Its Islamic structuring expertise, and ESG-focused issuances cemented its position as a top Sukuk arranger.'
Bank ABC Islamic's focus on digital innovation, product development, and sustainable Islamic finance continue to set new standards in the industry. With this solid foundation, Bank ABC Islamic is ready to further develop the Islamic sustainable finance market globally, offering Shari'a-compliant banking products and services to a broader investor base. – TradeArabia News Service
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Trade Arabia
an hour ago
- Trade Arabia
M42, partners launch liquid biopsy testing in UAE
M42, a global health leader powered by technology, continues to pioneer artificial intelligence (AI) and medical and clinical solutions as part of its mission to revolutionise health in the UAE and globally. In a major advancement for precision oncology, M42 announced a strategic collaboration with AstraZeneca and SOPHiA Genetics to bring cutting-edge liquid biopsy testing to the UAE, aimed at advancing cancer diagnosis, informing treatment decisions, and enabling faster, accurate biomarker testing across a broad range of cancers. As part of the collaboration, M42 will integrate SOPHiA GENETICS' MSK-ACCESS, powered with SOPHiA DDM technology, into its testing infrastructure, enabling non-invasive genomic profiling of cancers through a simple blood draw. This approach does not replace but rather complements routine cancer screenings and is designed for patients who are unable to undergo a solid tumor biopsy, enabling them to be matched with a precision therapy tailored to their specific cancer profile. Over the next 12 months, the partnership will enable liquid biopsy testing access across select leading hospitals across the UAE, providing patients with faster, less invasive biomarker insights compared to traditional tissue biopsies, while also strengthening testing infrastructure and capabilities for a wide range of cancers in the UAE. The new testing programme will initially target lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the most critical cancer burdens in the region. Validation studies are set to commence shortly at Cleveland Clinic Abu Dhabi, marking a key milestone toward the full clinical launch planned for the latter part of Q2 2025. Over time, the collaboration will serve as a foundation for broader expansion across the Middle East, excluding Saudi Arabia, delivering world-class precision oncology solutions to a wider population. Albarah El-khani, Senior Vice President, Operations, Integrated Health Solutions at M42, said: "At M42, we are committed to transforming care through innovation and collaboration. By partnering with AstraZeneca and SOPHiA GENETICS, we are bringing world-class liquid biopsy technologies to the UAE, empowering clinicians to deliver more precise and less invasive cancer care. This collaboration reflects our vision of democratizing health by making advanced diagnostics accessible to more patients, supporting not just early diagnosis but also real-time treatment monitoring and cost-effective, precise, predictive, and personalized care." Sameh El Fangary, Cluster President GCC, AstraZeneca, shared:"At AstraZeneca, we are leading the way in the application of precision medicine. Our work, and our collaborations with partners across industry, are driving towards better treatments for patients as well as a more sustainable future for healthcare systems. Through our latest partnerships, we are committed to transforming cancer care for millions in the region by advancing early diagnosis and optimizing patient pathways from detection to therapy.'
Trade Arabia
an hour ago
- Trade Arabia
Dubai hospitals to use geko device for patients
Dubai-based Genesis Healthcare, Dubai London Hospital and Mediclinic Parkview Hospital have adopted Sky Medical's innovative geko device to accelerate chronic wound healing (leg ulcers), prevent and treat lower limb oedema (swelling) and to prevent venous thromboembolism (VTE - blood clots) in medically ill and immobile patients. The size of a small wrist-watch, the geko device is a wearable neuromuscular electrostimulator that is applied to the surface of the skin just below the knee. It delivers a gentle electrical pulse, once per second, to the common peroneal nerve, activating the calf and foot muscle pumps, increasing venous, arterial, and microcirculatory blood flow at a rate equal to 60% of walking, replicating the effects of exercise without a patient having to move, said global medical device manufacturer Sky Medical Technology. Dr Ibrahim Riza, Consultant Vascular and Endovascular Surgeon, said: 'The geko device has been a game-changer in my practice. External compression, multi-layer bandaging, and drugs are the current standard of care for increasing blood circulation, but they do not work for all conditions. External compression and bandaging therapies can be complex to apply and uncomfortable to wear, leading to poor patient compliance, and drugs can carry an unpredictable bleed risk. The geko device overcomes these challenges and is uniquely positioned to address significant unmet needs when drug and current compression devices are impractical or contraindicated. As well as chronic wound healing and post-stroke VTE prevention, the geko device is highly effective in addressing lymphedema and maternity and travel-related oedema. 'One of its biggest advantages is ease of use. The geko device is lightweight, silent, and completely non-invasive. Patients can wear it while sitting, lying down, and moving around, making it ideal for immobile patients and for those who are active in managing their recovery following surgery. By offering my patients the geko device, I provide them with a safe, comfortable, and effective way to support their vascular health, without the need for drugs or bulky equipment.' Sky Medical Technology CEO and Founder Bernard Ross: 'I am delighted that Dr Ibrahim Riza and his clinical team are benefiting from the geko device, which provides an effective and non-invasive way to manage vascular health and enhance recovery. We are proud to be partnered with hospitals and clinicians in Dubai who share our vision for advanced therapies that can deliver better patient outcomes and healthcare system savings.'
Trade Arabia
an hour ago
- Trade Arabia
UAE's SCA urges Finfluencers to register
The UAE's Securities and Commodities Authority (SCA) has called on all financial influencers (Finfluencers) operating across digital platforms and media channels to proactively register and obtain official authorised 'Finfluencer' status. This designation requires full compliance with regulatory standards to ensure content transparency and safeguard the rights of market participants, a Wam news agency report said. Waleed Saeed Al Awadhi, CEO of the SCA, stated: 'In today's rapidly evolving digital financial ecosystem, regulating Finfluencers activity has become imperative. Finfluencers play a pivotal role in shaping investor decisions. Official authorisation by the SCA underscores their commitment to professional standards and reinforces public trust in the integrity of financial content.' The SCA offers eligible individuals the opportunity to apply for authorised Finfluencer status, allowing them to share investment analyses and offer recommendations related to approved financial instruments or entities through digital or traditional media, as long as they remain in strict compliance with the SCA's standards. To further encourage adherence, the SCA is granting a three-year waiver on registration and renewal fees, along with access to legal advisory services. In parallel, the SCA urges the public to verify a Finfluencer's authorisation status before engaging with their content or acting on their recommendations. The SCA also encourages prompt reporting of any unauthorised activities via its official website or call centre, stressing that interactions with unauthorised individuals or entities may pose significant financial risks to investors. The SCA reiterates that public awareness and active engagement are the first line of defence against unreliable or unregulated financial content. To apply to become an Authorised Finfluencer recognised by the SCA, or to report non-compliant practices, interested people should visit the SCA website or call the toll-free number 800722823.
